The effect of anagliptin on blood glucose and serum lipids in Patients with type 2 diabetes mellitus

The effect of anagliptin on blood glucose and serum lipids in Patients with type 2 diabetes mellitus - The effect of anagliptin on blood glucose and serum lipids in patients with type 2 diabetes mellitus

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000030532

Enrollment

Registered

2017-12-25

Start date

2018-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes mellitus

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Before test registration -anagliptin within 2 weeks outpatient 2. Type 2 diabetes 3. LDL-C more than 120 mg/dL 4. No plan to add other OHA 5. Age more than 20, less than 85 6. Patients with written IC

Exclusion criteria

Exclusion criteria: 1. Allergy for anagliptin. 2. Severe ketosis, diabetic coma severe infection, before operation, severe trauma 3. Severe renal dysfunction including hemodialysis or peritoneal dialysis (SCr:more than 1.5mg/dl ) 4. Pregnancy 5. Patients judged by the investigator to be ineligible for some other reason

Design outcomes

Primary

Measure	Time frame
Change of HbA1c and lipid levels(LDL-C,MDA-LDL,RLP-C)	—

Secondary

Measure	Time frame
1. Change of HbA1c and lipid levels 2. The change of glycemic and lipid parameters 3. The analysis of baseline characteristics 4. The analysis of backgorund factors which affect glycemic and lipid control	—

Countries

Japan

Contacts

Public ContactYoshihisa Okamoto

Japan Community Health care Organization, Yokohama Hodogaya Central Hospital Department of Medicine(Endocrinology, Diabetes and Metabolism)

okamoto-ykh@umin.ac.jp045-331-1251

Outcome results